Neuromuscular Disease Foundation
Treatments & Research
There is currently no FDA-approved treatment for GNE myopathy in the United States. Research is active, and a treatment has been approved in Japan
Clinical Trial Opportunities
Now Recruiting • Phase 1/2
UX016 Clinical Trial
Conducted by Ultragenyx
UX016 is an investigational oral therapy being studied in adults with GNE myopathy. It combines sialic acid with a fatty-acid component intended to improve delivery in the body.
The study is evaluating safety, how the body processes UX016, and its potential effects on muscle strength and function.
Other Treatment Approaches
Preclinical research
GNE Gene Therapy
Gene therapy aims to deliver a working copy of the GNE gene into muscle cells using a modified viral vector. It adds a copy rather than repairing each individual mutation.
NDF’s GNE-001 program is in preclinical development. Human safety and effectiveness have not been established. Progress toward clinical trials depends on further studies, manufacturing, regulatory review, and funding.
Approved in Japan
Acenobel
Acenobel, an extended-release sialic acid treatment, received approval in Japan on March 26, 2024. This is a Japanese regulatory approval, not an FDA approval in the United States.
The Japanese approval followed studies in Japan. A separate international Phase 3 study of extended-release sialic acid did not demonstrate improved muscle strength compared with placebo.
Sources: Approval announcement · Japanese regulatory review (PDF) · International Phase 3 study
What Other Studies Have Found
Research findings help guide the next steps. Early signals do not always translate into a proven treatment benefit.
Extended-release Sialic Acid: International Phase 3 Study
An international study of 89 people with GNE myopathy compared extended-release sialic acid with placebo over 48 weeks. It did not demonstrate a significant benefit on the primary muscle strength outcome. This formulation and study are distinct from the current UX016 trial.
Accordion Item6′-sialyllactose (6′-SL): Small Exploratory Studies
6′-SL is being investigated as a way to increase sialic acid. A small study reported increased sialic acid levels and improvements in some muscle measures.
A later 48-week pilot study of 11 participants found mixed results. Most muscle strength measures and functional assessment scores did not show significant differences between groups, although some imaging findings were encouraging. Larger studies are needed to establish whether it provides a meaningful benefit.
These findings do not establish that commercially available supplements treat GNE myopathy. Discuss supplements with your clinician and any clinical trial study team.
ManNAc: Results from the MAGiNE Trial
ManNAc is a sugar involved in the production of sialic acid. Earlier research suggested potential benefits, leading to the randomized MAGiNE trial with 54 participants.
Results reported in a 2026 conference abstract did not show a statistically significant benefit on the primary measure of muscle strength decline compared with placebo. The linked report is a conference abstract, rather than a full study publication.
Questions about Where to Start?
Talk with your care team about treatment options and research participation. NDF can help you find information and connect with resources.
This page provides educational information and does not replace medical advice. Trial availability and eligibility can change. Confirm current details directly with the study team.